We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.14 | 1.90% | 7.50 | 660,801 | 09:05:09 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 7.00 | 8.00 | 7.52 | 7.25 | 7.25 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 55.2M | -40.22M | -0.0084 | -8.93 | 350.81M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 14:00:17 | UT | 10,000 | 7.54 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/12/2024 | 13:41 | UK RNS | Allergy Therapeutics PLC Exercise of Options and Total Voting Rights |
| 17/12/2024 | 16:19 | UK RNS | Allergy Therapeutics PLC Block Listing Interim Review |
| 16/12/2024 | 15:33 | UK RNS | Allergy Therapeutics PLC Result of Annual General Meeting |
| 04/12/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Positive Interim Data from PROTECT Trial |
| 27/11/2024 | 16:52 | ALNC |  IN BRIEF: Allergy Therapeutics treats first patient in allergy trial |
| 27/11/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC First Patient Dosed in G308 Paediatric Trial |
| 25/11/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Submission of MAA for Grass MATA MPL |
| 21/11/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Notice of 2024 Annual General Meeting |
| 06/11/2024 | 11:22 | ALNC | Allergy Therapeutics annual loss narrows thanks to reduced expenses |
| 06/11/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Audited Preliminary Results 2024 |
Allergy Therapeutics (AGY) Share Charts1 Year Allergy Therapeutics Chart |
|
1 Month Allergy Therapeutics Chart |
Intraday Allergy Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/1/2025 | 12:06 | Allergy Therapeutics - AGY - | 5,269 |
| 07/5/2022 | 14:09 | PEANUT PEANUT PEANUT ALLERGY COMPLETE PREVENTION | 1 |
| 06/5/2022 | 10:08 | Allergy Therapeutics | - |
| 26/5/2021 | 10:10 | Argosy Minerals: Aussie Diamond hunter in SoAfrica | 9 |
| 14/7/2016 | 20:04 | Mike Mitchell Panmure Gordon who covers Allergy Therapeutics PLC (LON:AGY) | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 14:00:17 | 7.54 | 10,000 | 754.00 | UT |
| 13:38:25 | 7.75 | 2,503 | 193.98 | O |
| 11:30:41 | 7.77 | 408 | 31.68 | O |
| 11:27:46 | 7.36 | 10,000 | 736.00 | O |
| 11:00:21 | 7.54 | 80,000 | 6,032.00 | UT |
| Top Posts |
|---|
Posted at 20/12/2024 20:10 by totally banjo "The total number of shares issued is 4,766,439,938 Ordinary Shares of 0.1 pence each. 92.62% of the shares are not in public hands, as at 13 December 2023."I brought this up a few weeks/months ago I think with SkyGem Acquisition Limited (ZQ Capital) having 65% and Southern Fox Investments 27.43% leaving only about 7.5% in 'public hands'! Therefore a good part of the 7.5% will be either held by long term holders (like me although I don't have as many anymore) or been bought over the last year (probably for the longer term) hence the rise in SP! Again therefore, with the huge potential of AGY over the next year/years where does the share price go during this time as there will come a point where you can't buy any shares or am I being thick? (I've had a few early pints :-) ) |
Posted at 19/12/2024 13:18 by totally banjo Part from an article today:Allergy Therapeutics: A story of resilience and transformation Published: 12:32 19 Dec 2024 GMT Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is writing a story of resilience and transformation. Putting behind it manufacturing setbacks, the company has redefined its trajectory with a bold strategy centred on innovation. Its pioneering short-course therapies, designed to tackle conditions such as hay fever and peanut allergy, promise not only to disrupt traditional treatments but to drive significant growth and value in the process. Its August results hinted at a turning point. In the second half of the financial year, the company posted its first revenue growth since 2021, a milestone that signals progress but also serves as a prelude to something potentially transformative. That journey has already begun with the Grass MATA MPL treatment - for grass pollen allergies - which late last month was submitted for regulatory approval in Germany. If greenlit by the Paul-Ehrlich-Institu “We have worked around the clock to get the trading business back to growth,” says CEO Manuel Llobet. “The Peanut project is very exciting, but maybe in the short term, more interestingly, is the regulatory submission we have made [for Grass MATA MPL], where the primary endpoint was met.” Strong balance sheet More recently, Allergy Therapeutics has strengthened its financial position with a new £40 million debt line from Hayfin Healthcare Opportunities, comprising a £20 million committed five-year term loan and a £20 million uncommitted incremental facility. Additionally, it has increased an existing loan facility by £10 million to £50 million. This sort of backing suggests Allergy Therapeutics may be onto something big, an assertion supported by analysts at the research house Cavendish. Using a discounted cash flow model, they have set a price target of 13p for stock in Allergy Therapeutics - a 124% premium to the current share price. Specifically, the Cavendish number crunchers believe VLP Peanut could achieve blockbuster status in the US with annual sales in excess of $1 billion, while it expects a not-insubstantial $300–400 million peak sales from Grass MATA MPL. Cavendish is also predicting strong top-line growth to the previously sedentary existing commercial operation and believes the company’s technology provides a strong moat (Warren Buffett’s term for competitive protection) to the business. Summarising the 37-page research ‘opus’, Cavendish said it believes Allergy Therapeutics has the ability, based on its two key assets, to generate “significant potential future value for shareholders”. |
Posted at 18/12/2024 11:25 by totally banjo Yesterdays announcement Re 'Block Listing Interim Review' relates to one of the resolutions passed the day before at the AGM:Approval of Special Awards The Company is seeking approval from the Shareholders to authorise the Directors to finalise and implement arrangements for the grant of the special, out of cycle, long term incentive awards to the Company's senior executive team (the "LTIP Awards") and additional option awards to the Company's employees (the "Option Awards" and, together with the LTIP Awards, the "Special Awards"). The LTIP Awards are intended to incentivise and reward extraordinary levels of share price growth and shareholder value creation over a five-year period, as more patients benefit from the Company's immunotherapies. The remuneration committee of the Company believes that the mix of remuneration awards will ensure a balance between strong growth and reaching for full potential. In order to make the Special Awards, the Company needs to make certain amendments to its 2023 Long Term Share Incentive Plan (the "Plan") and to adopt a sub-plan to the Plan. No amendments will be made to the overall Plan limit. The maximum aggregate number of ordinary shares under option pursuant to the LTIP Awards will be approximately 215 million, representing 4.5% of the Company's issued share capital as at 14 November 2024. The Company anticipates that the Option Awards will in aggregate be granted over a maximum of 1.7% of the Company's issued share capital as at 14 November 2024. |
Posted at 09/12/2024 14:44 by totally banjo Grass MATA MPL immunotherapy vaccine completed the G309 and G306 studies which included people/subjects from the USA along with the USA relevant regulators being closely involved, which assists in the application for FDA (USA approval) further down the road.I believe the statement "Concurrently, we are exploring US registration opportunities" will be for the initial G307 study involving just USA subjects before the FDA route can commence. Grass MATA MPL immunotherapy vaccine started the Marketing Authorisation Application for Germany 25th Nov 2024 via the Paul Ehrlich Institute (PEI) and if successful paves the way for sales in the largest market in Europe! There's still a way to go but if AGY keep reporting positive news and results it all adds up in giving the share price a firm foundation for further rises, in my humble opinion of course! |
Posted at 21/11/2024 11:53 by vergeltung Agreed @jimmyloser, but you know my views. Incentives are right and proper but because the current team are the same geniuses as brought the company to its knees, all but wiping out the value of our shares, this looks like rewarding those failures. The talk of aligning to increase the share price is hollow. The exercise price of these options should be current market; it's not, these are free shares.I have been around and investing in this sector for decades; there are lots of examples of management failure. Never have I seen the whole board and the CEO stay in place after so lamentable a performance. If anyone had grasped the nettle, if the chairman had done the decent thing and accepted that disaster had happened on his watch and resigned to allow his successor to review the exec team - I repeat, this would have been normal, good governance - then I would be the first to say go ahead! Let's set aside an amount greater 4.5% for the team tasked with delivering. But 215 million shares(!!) for Llobet et al seems ridiculous. Why would more stock options make him any smarter than he was in October '22 when he decided to shut down production? |
Posted at 08/11/2024 15:02 by vergeltung I hate to introduce a negative note to this up-beat exchange, but a couple of the items in this RNS really irritated me:• 'Revenue of £55.2m (2023: £59.6m) from commercial portfolio, with encouraging H2 performance showing first period of half-year growth since 2021. Full year revenue impacted by supply constraints to key markets of Germany and Spain.' We all know why there has been no period of half-year growth since 2021 - in October 2022, just when H1’22 making should have been at full spate, the management decided to initiate its “short-term pause in UK manufacturing to optimise quality systems and accelerate capacity improvements” - which precipitated non-supply of markets, the collapse of the share price, suspension from AIM and series of emergency financing measures of increasing cost which hit us all so hard. So well done, Llobet and crew, on eking out a 2% increase but that you should be 'encouraged' by this painfully slow recovery from your own self-imposed, catastrophically-tim • 'Implemented new Long Term Incentive Plan to align key leadership interests with long-term shareholder value creation and strategic objectives.' Amazingly this is being represented as an achievement! It means Llobet is now reset to the new share price environment, - options with an exercise price of 0.1p - that’s right 1/10 of a penny - meaning he will not suffer from the share price having gone from the 20-30p range to the 1-5p range as a consequence of his decisions and actions. He has 9.65m options worth nearly £500k. I hardly need point out that the rest of us would have had to invest in the equity funding at 1p - 10x his exercise price - to avoid complete wipe-out. And with the exercise price so low the options have value even if the price collapses. Some incentive! This makes me fear the board and management at AGY have learned no lessons from their lamentable performance since 2021 despite (finally!) recognising the effect it has had on minority shareholders. So yes, we do have a longer cash runway (at considerable cost) and the development portfolio does hold great potential, so we are just one announcement away from a 2x price movement - but it's high risk and surely we can do better than this team to deliver for shareholders? |
Posted at 07/10/2024 23:52 by totally banjo Hi Jimmy, one thing I've noticed, the market from when I started nearly 30 years ago and after having a near 10 year lapse due to getting badly burnt has changed quite dramatically! There appears to be less interest or maybe a sea change (whatever that means) in the way shares are bought and sold especially in AIM and the 'longer view' or maybe it's just me!AGY have stated they expect the results for the year ended 30 June 2024 to be published by end of this month which they didn't have to say but it's good to hear anyway, as it gives everyone a rough time for information, which is great! Over the next few weeks (Results) and months there is so much positive news that could easily get the share price into double figures as in 10p or even a lot further! If the Results can show an increase in revenue on their existing products after investment in improving their manufacturing facilities to cope with the demand for their products than that's a massive bonus! The ongoing trials along with getting approvals for their various new products is and should be classed as 'potential' regarding any share price movement as anything could happen! I bought some more last week as I believe the company has a very exciting future ahead but that's just my opinion! |
Posted at 05/9/2024 00:35 by totally banjo Got beat 6-3 at pool tonight :-( but I won singles and doubles games :-)Anyway, in my opinion over the shorter term is seeing increased revenue in Europe due to their expanded manufacturing facilities to facility the demand for their existing products is key! There is so much potential (that word again) for this company to make massive gains for existing and new shareholders regarding the results of their various trials but they will take time (years) before they are revenue generating! If AGY issues the results of the PROTECT trial in Q4 2024 and if it's positive the share price will rocket! As said before, very boring stock to hold but could pay huge and I mean huge dividends from this current share price in a year or three or before if they get bought out! Do your own research as always! |
Posted at 04/9/2024 10:24 by totally banjo The PROTECT trial estimated completion date is a few months into 2025 but this, I believe, is the follow up on subjects after the trial is finished.Therefore it is likely that we will get the results of the trial in Q4 2024 which will, if positive, give AGY exposure on the global stage which should be reflected in the share price I'm very positive for AGY future but it does need highlighting that the various on going trials will take time to become revenue generating. It is also quite possible AGY could be bought out before this time! |
Posted at 29/12/2023 11:31 by vergeltung I have not read the details (not sure they will be public) but assuming all the important points to be covered in the press release, I am encouraged by this development.The new financing is best seen as part debt, part equity. AGY is not a good credit risk. Borrowing money at 12% is not expensive (you would not get a loan from an unconnected commercial lender on this interest alone). So the lending requires an equity 'kicker'. The warrants are worth little until the share price approaches 4p. Imagine selling call options on AGY equity with a strike price of 4p (i.e. about 60% out-of-the-money) - what would their price be? However, once the shares go over 4p the warrants boost the return on the lending. If the share price rises to 6p (more than 2x the current price), for example, the return to the lenders is 62% after 12 months. Greedy! But that is a big 'if'. Furthermore, if the warrants are issued they entitle the lenders to buy new shares at 4p - i.e. if all 1bn warrants are exercised the company receives a further £40m in cash. This funding like an optimistic move - much of the lenders' return depends upon the share price going up 60% from now (2.5p) and I am pleased that the insiders here appear to have confidence that this will happen. I do think this fundraise is good for the company and this seems to be the view of the market. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
